Loading
companiesCompany
IMPACT Therapeutics
IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China.
Also called: Impact Therapeutics, Inc.IMPACT Therapeutics (Shanghai)
Overview
IMPACT Therapeutics, headquartered in Shanghai, develops inhibitors of the DNA damage response. Its PARP inhibitor senaparib (IMP4297) improved progression-free survival as first-line maintenance in advanced ovarian cancer in the phase 3 FLAMES trial and gained Chinese approval, and its Wee1 and ATR inhibitors follow in earlier trials. Its trials are registered on ClinicalTrials.gov under IMPACT as lead sponsor.
Headquarters
Shanghai, CN
Scorecard
All companies#323of 1244 companies, score 12
- phase 3 +3
- targets +2
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 1 targets, 6 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Phase 3small molecule (oral PARP inhibitor)
Senaparib (IMP4297) · Sepalna
Senaparib is an oral PARP inhibitor from IMPACT Therapeutics tested as maintenance treatment after first-line chemotherapy for advanced ovarian cancer. On 17 September 2026 the EMA's medicines committee recommended EU approval under the name Sepalna; the European Commission's decision is pending.
Similar pages
- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Ovarian cancer.
- CompanyEikon Therapeutics
Shares A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors., A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors.
- CompanyPregLem
- CompanyAgennix
- CompanyImmunitor
- CompanyLisata Therapeutics
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
cancers
technologies
drugs
Phase 3small molecule (oral PARP inhibitor)
Senaparib (IMP4297) · Sepalna
terms
trials
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsA Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerA Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors